

REVIEW

Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis

Shubham Misra¹  | Manabesh Nath¹  | Vijay Hadda² | Deepti Vibha¹ 

¹Department of Neurology, All India Institute of Medical Sciences, New Delhi, India

²Department of Pulmonary, Critical Care & Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India

Correspondence

Deepti Vibha, Department of Neurology, Neurosciences Centre, All India Institute of Medical Sciences, Room No.: 707, 7th Floor, Ansari Nagar, New Delhi, India.
Email: deeptivibha@gmail.com

Abstract

Background: Several therapeutic agents have been investigated for treatment of novel coronavirus 2019 (nCOV-2019). We conducted a systematic review and meta-analysis to assess the efficacy of various treatment modalities in nCOV-2019 patients.

Methods: A literature search was conducted before 29 June 2020 in PubMed, Google Scholar and Cochrane library databases. A fixed-effect model was applied if $I^2 < 50\%$, else results were combined using random-effect model. Risk ratio (RR) or standardized mean difference (SMD) along with 95% confidence interval (95% CI) was used to pool the results. Between-study heterogeneity was explored using influence and sensitivity analyses, and publication bias was assessed using funnel plots. Entire statistical analysis was conducted in R version 3.6.2.

Results: Fifty studies involving 15 in vitro and 35 clinical studies including 9170 nCOV-2019 patients were included. Lopinavir-ritonavir was significantly associated with shorter mean time to clinical recovery (SMD -0.32 ; 95% CI -0.57 to -0.06), remdesivir was significantly associated with better overall clinical recovery (RR 1.17; 95% CI 1.07 to 1.29), and tocilizumab was associated with less all-cause mortality (RR 0.38; 95% CI 0.16 to 0.93). Hydroxychloroquine was associated with longer time to clinical recovery and less overall clinical recovery. It additionally had higher all-cause mortality and more total adverse events.

Conclusion: Our meta-analysis suggests that except in vitro studies, no treatment has shown overall favourable outcomes in nCOV-2019 patients. Lopinavir-ritonavir, remdesivir and tocilizumab may have some benefits, while hydroxychloroquine administration may cause harm in nCOV-2019 patients. Results from upcoming large clinical trials may further clarify role of these drugs.

KEYWORDS

humans, interventions, nCOV-2019, novel coronavirus 2019, treatments

1 | INTRODUCTION

The novel coronavirus 2019 (nCOV-2019) has now encompassed more than 200 countries since a cluster of cases were initially reported in Wuhan, China on 31 December 2019.¹ As of 5 July 2020, 11 388 558 people have been infected globally from nCOV-2019, while 533 638 have died of this severe infection.² The nCOV-2019 belongs to the Coronaviridae family and has structural similarities to the betacoronavirus that has caused two epidemics in the past 18 years: severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-Cov).³

No drug or therapeutic agent has yet been approved by the United States—Food and Drug Administration (USFDA) for treating nCOV-2019 pneumonia patients. Based on the initial results obtained from certain *in vitro* studies,^{4,5} non-randomized trials⁶ and interim analysis of some randomized controlled trials (RCTs),⁷ hydroxychloroquine and remdesivir, received FDA emergency use authorization for nCOV-2019.^{8,9} However, recent RCTs published on these respective drugs need evidence synthesis for their usage in nCOV-2019 patients.^{10,11} FDA cautioned against the use of chloroquine or hydroxychloroquine outside clinical trial settings due to high risk of associated adverse events.¹² With more than 500 trials already registered in clinicaltrials.gov on the treatment of nCOV-2019, it is imperative to investigate the available evidence till date and assess each treatment in terms of benefit or harm to the nCOV-2019 patients.

The aim of this systematic review and meta-analysis was to pool the initial evidence available from RCTs, non-RCTs, observational and *in vitro* studies for analysing the benefit/harm of various treatment modalities including antiviral, corticosteroid treatment, plasma therapy and traditional medicines administered to nCOV-2019 pneumonia patients. The results of this systematic review and meta-analysis might be useful in designing future clinical trials and providing guidelines.

2 | METHODS

2.1 | Electronic search

Electronic databases including, PubMed, EMBASE, Medline, Google Scholar, Cochrane library and clinicaltrials.gov were searched till 29 June 2020. The following MeSH terms or free text terms were used: '2019 novel coronavirus', '2019 nCOV', 'COVID19', 'SARS-CoV-2', 'drug therapy', 'antiviral therapy', 'symptomatic treatment', 'immunotherapy'. The detailed search criteria are given in the Appendix S1. Furthermore, the reference

list of all the relevant identified articles was thoroughly searched. Only those articles were included whose full texts were available in English language. Studies published on human subjects after 31 December 2019 since the nCOV-2019 outbreak initiated, were only searched. The protocol for this systematic review and meta-analysis was registered in PROSPERO (ID: CRD42020175792), and there were no major deviations from the published protocol in PROSPERO.

2.2 | Population

Subjects diagnosed with pneumonia caused by new coronavirus 2019 infection (nCOV-2019) confirmed positive on high-throughput sequencing or real-time reverse-transcription polymerase chain reaction analysis of throat swab specimens, serology or culture.

2.3 | Intervention

Various specific, preventive and immune treatments administered to the nCOV-2019 patients.

2.4 | Comparator

nCOV-2019 patients receiving standard care only or placebo treatment or standard care with a comparator drug.

2.5 | Outcome

2.5.1 | Outcome for *in vitro* studies

Average half-maximal inhibitory concentration (IC₅₀), average half-maximal effective concentration (EC₅₀), average cytotoxic concentration (CC₅₀) and average selectivity index (SI) of the various drugs included in the systematic review.

2.5.2 | Outcome for clinical studies

(a) All-cause mortality, (b) total adverse events, (c) overall clinical recovery defined as the number of patients becoming negative for nCOV-2019 or significant improvement on chest CT and getting discharged from the hospital and (d) time to clinical recovery defined as the time taken in number of days for the negative conversion of nCOV-2019 or significant improvement on chest CT and getting discharged from the hospital.

2.6 | Inclusion and exclusion criteria

The criteria for the inclusion of studies in our systematic review and meta-analysis were as follows:

For inclusion of in vitro studies: (a) studies aimed at evaluating the efficacy of multiple drugs/treatment choices for nCOV-2019, (b) studies should have reported data on inhibitory effect and cytotoxicity of the drug and (c) only published studies.

For inclusion of clinical studies: (a) randomized controlled trials (RCTs), non-RCTs, cohort studies and case-control studies; (b) studies aimed at evaluating multiple therapeutic choices for nCOV-2019; (c) studies must have a control group comparing the primary treatment drug to either standard care/control or placebo or studies assessing the primary treatment drug with a comparator drug; (d) conducted on human subjects only; and (e) only published studies.

The following clinical and in vitro studies were excluded from our systematic review and meta-analysis: (a) conducted on animal models; (b) unpublished studies; (c) ongoing registered clinical trials; (s) desired outcome data not reported; (e) single arm studies/trials where the primary treatment drug is not compared to either standard care alone, placebo or standard care with a comparator drug (criteria for clinical studies). This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol (PRISMA-P) 2015 guidelines.¹³

2.7 | Data extraction

All titles and abstracts retrieved by searching available literature were screened independently by two authors (SM and MN) against the eligibility criteria. The information extracted from each eligible study included the first author, year of publication, study design, sample size, interventions (including type of treatment administered), outcome measures and main results. Any disagreement was resolved by mutual consensus among all the authors (DV, VH, SM, MN).

2.8 | Risk of bias assessment

The quality assessment was done for only the clinical studies included in our systematic review and meta-analysis by two independent authors (SM and MN) using the new Cochrane risk of bias tool for randomized controlled trials (ROB-2) for RCTs and Newcastle-Ottawa Scale (NOS) for non-RCTs, cohort and case-control studies.^{14,15} Any disagreement was

resolved by consulting with the remaining authors of the review.

The risk of publication bias was assessed by using Funnel plots, and the asymmetry of the funnel plot was investigated using the Egger's regression test.¹⁶

2.9 | Statistical analysis

Dichotomous variables were represented by number (percentage), and the continuous variables were represented by mean and standard deviation (SD). If median, ranges and/or interquartile range were reported, then they were converted to mean and SD using the formula depending upon the sample size given by Wan et al.¹⁷ A meta-analysis was performed only for clinical studies and for those treatments in which required outcome data could be pooled from two or more studies. For dichotomous variables, the data were pooled using risk ratio (RR) and 95% confidence interval (95% CI), while for continuous variables, the data were pooled using standardized mean difference (SMD) and 95% CI. Heterogeneity among the included studies was investigated using Cochran's Q statistic, I^2 metric tests and by using prediction intervals. A fixed-effect model was applied if I^2 was <50%, else a random-effect model was used to pool the results. Labbé plots were used to determine the trend and between-study heterogeneity present in the binary outcome meta-analysis. The source of heterogeneity was further assessed by using the influence diagnostic tools and by conducting the sensitivity analyses and meta-regression analyses. All the statistical analysis was conducted using R version 3.6.2.

3 | RESULTS

Initial search yielded 1490 articles by searching various databases for published and preprint articles. After screening 928 articles, 377 full-text articles were reviewed for eligibility, and finally, 50 studies were included in our systematic review and meta-analysis. Further, out of the 50 included studies, 15 were in vitro studies and 35 were clinical studies. The meta-analysis was finally conducted on 23 clinical studies. Figure 1 represents the PRISMA flow diagram for the inclusion of studies in our systematic review and meta-analysis. The PRISMA checklist is available in the Appendix S3.

3.1 | Results from the systematic review of in vitro studies

Overall, 15 in vitro published studies were included in the systematic review, which comprised majorly of treatments done on Vero E6 cells for viral titration, drug inhibition




FIGURE 1 PRISMA flow diagram for the systematic review and meta-analysis

and cytotoxicity analyses. Nine studies were included from China,^{4,5,18-24} three from United States of America (USA),²⁵⁻²⁷ one each from Germany,²⁸ Netherlands²⁹ and Australia.³⁰

There were two studies^{5,20} involving the antimalarial drug on hydroxychloroquine, which had chloroquine as a positive control in both the studies. The studies had a

wide range of multiplicity of infection (MOI) from 0.01 to 0.8 and an average half-maximal effective concentration (EC₅₀) of 6.84 μ M [0.72-12.96] in the treatment arm as compared to 6.415 μ M [5.47-7.36] in the control arm. The two studies showed potency in inhibiting nCOV-2019 in vitro in Vero cells. While the cytotoxic concentration

(CC₅₀) of 249.50 μ M and selectivity index (SI) of 61.45 at an MOI of 0.01 in one study²⁰ were lower compared to the positive control, the EC₅₀ value of hydroxychloroquine was higher than chloroquine. These studies depicted that hydroxychloroquine had better efficacy and lesser cytotoxicity in inhibiting nCOV-2019 than chloroquine in vitro but a higher dosage might be required for effectiveness, which could have adverse consequences.

Two studies^{4,23} involving the broad-spectrum antiviral remdesivir with MOI in the range of 0.02-0.05 exhibited average EC₅₀ of 11.96 μ M, CC₅₀ greater than 100 μ M and SI >129.87. Remdesivir showed promising results in vitro and depicted potency inhibiting viral proliferation in Vero E6 cell line. Not only remdesivir was able to block nCOV-2019 infection at lower concentrations it also had higher selectivity towards the viral cells that meant it had lower toxicity towards the host cells.

One study each involving 47D11 H2L2 antibody,²⁹ arbidol,¹⁸ auranofin,²⁷ beta-d-N4-hydroxycytidine,²⁵ darunavir,²⁸ antibodies n3086/n3113,²⁴ interferon- α /interferon- β ,²⁶ ivermectin,³⁰ lianhuqingwen,²¹ chloroquine,⁴ lopinavir,²³ emetine hydrochloride,²³ homoharringtonine²³ and Pudilan Xiaoyan oral liquid²² had a wide range of EC₅₀ [0.15-100 μ M] or IC₅₀ [0.08-411.2 μ M] values for MOI of [0.05-2]. However, each of these compounds demonstrated the potential to stall the process of viral replication and growth through inhibiting viral titre in Vero, Calu3 and Huh7 cell lines.

There was one in vitro study¹⁹ on the phytochemical extracts from six Chinese traditional medicinal plants viz. *Cimicifuga rhizoma*, *Meliae cortex*, *Coptidis rhizoma*, *Phellodendron cortex*, *Sophora subprostrata radix* and *Mountan cortex radiceis*. Extracts from five of the six plants showed potential as herbal medicine by inhibiting nCOV-2019 infection in both A59 and Vero cells with significant EC₅₀ [2.0 \pm 0.5-27.5 \pm 1.1 μ g/mL], CC₅₀ [71.3 \pm 7.2-334.3 \pm 7.0 μ g/mL] and SI [11.1-34.9] values.

All the studies had an incubation time (hours postinfection) of treatment ranging from 24 to 72 hours on average with a median of 48 hours. Table 1 depicts the baseline characteristics of in vitro studies included in our systematic review.

3.2 | Results from clinical studies

A total of 35 clinical studies with 9170 nCOV-2019 pneumonia patients were included in the systematic review out of which 5563 (60.67%) patients were males. The overall mean age of the subjects present in the included studies was 56.34 \pm 14.33 years. We included 12 RCTs, 3 non-RCTs and 20 observational (including retrospective/prospective cohort, case-control) studies. Eighteen studies were from

China,^{10,11,31-46} six from USA,⁴⁷⁻⁵² five from Italy,⁵³⁻⁵⁷ two from France^{6,58} and one each from Brazil,⁵⁹ Hong Kong,⁶⁰ Spain⁶¹ and Greece.⁶²

There was no significant difference in the mean age and sex distribution between any of the treatment and comparator groups included in our meta-analysis. Table 2 depicts the baseline characteristics of clinical studies included in the systematic review and meta-analysis. Since only limited clinical trials and observational studies have been published till date, the data from several studies could not be pooled together to assess any of the four outcome measures. Figure S1 in the Appendix S2 illustrates the effect of various treatment modalities in individual studies in terms of all-cause mortality, total adverse events, overall clinical recovery and time to clinical recovery.

3.3 | Results from the meta-analyses of clinical studies

3.3.1 | Hydroxychloroquine vs control groups

Eight studies^{6,10,31,32,47-49,58} consisting of 3400 nCOV-2019 cases were included in the meta-analysis and were divided into two groups: 1522 subjects to hydroxychloroquine group and 1878 subjects to control group. Compared to the control group, hydroxychloroquine had an increased risk of having total adverse events (RR 1.82; 95% CI 1.57 to 2.12) and was associated with a longer time to clinical recovery (SMD 0.55; 95% CI 0.21 to 0.89). However, hydroxychloroquine was not found to be significantly associated with all-cause mortality (RR 1.22; 95%CI 0.76 to 1.95) and overall clinical recovery (RR 0.93; 95%CI 0.84 to 1.04) (Figure 2A-D). However, through the Labbé plots, we did observe a trend that all-cause mortality was more towards the hydroxychloroquine group (Appendix S2) while overall clinical recovery was more in the control group (Figure 8A).

3.3.2 | Lopinavir-ritonavir vs control groups

Four studies³⁵⁻³⁸ consisting of 397 nCOV-2019 cases were included in the meta-analysis and were divided into two groups: 227 subjects to lopinavir-ritonavir group and 170 subjects control group. There was no significant association between the two groups in terms of total adverse events (RR 1.73; 95%CI 0.57 to 5.26) and overall clinical recovery (RR 1.08; 95%CI 0.94 to 1.24). Labbé plot observed a trend of having more adverse events towards the lopinavir-ritonavir group (Appendix S2). A borderline association was observed depicting a trend in terms of a shorter mean time (in days) to

TABLE 1 Baseline characteristics of in vitro studies on the inhibition and potential treatment of nCoV-2019

S. no.	Author, year	Country	Sample type	Assay used	Treatment	Control	EC ₅₀ or IC ₅₀	Incubation time (h)
1	Wang C, 2020 ²⁹	Netherlands	Vero E6	VNA	47D11 H2L2 antibody	Isotype	0.15 µg/mL	24
2	Wang X, 2020 ¹⁸	China	Vero E6	CCK8	Arbidol	-	4.11[3.55-4.73] µM	48
3	Rothan H, 2020 ²⁷	USA	Huh7	qRT-PCR	Auranofin	DMSO	1.4 µM	24, 48
4	Sheahan T, 2020 ²⁵	USA	Calu 3, Vero E6	CTG; Plaque	NHC	-	Vero: 0.3, Calu3: 0.08 µM	48, 72
5	Kim HY, 2020 ¹⁹	China	MHV-A59; Vero	MTT	Clrh; MEco; COrh; PHco; Ssr; Mcr	No extract	Clrh = 19.4 ± 7.0, MEco = 13.0 ± 1.4, COrh = 2.0 ± 0.5, PHco = 10.4 ± 2.2, Ssr = 27.5 ± 1.1, Mcr = 61.9 ± 6.1 µg/mL	12
6	Meyer S, 2020 ²⁸	Germany, USA, Belgium	Caco-2	MTT; CPE	Darunavir	RDV	> 100 µM	48
7	Wu Y, 2020 ²⁴	China	Vero E6	CPE	Group E antibodies: n3086, n3113	-	n3086 = 26.6, n3113 = 18.9 µg/mL	3
8	Yao X, 2020 ⁵	China	Vero	96 Well	HCQ	CQ	0.72 µM	24, 48
9	Liu J, 2020 ²⁰	China	Vero E6	CCK8	HCQ	CQ	12.96 µM	48
10	Mantlo E, 2020 ²⁶	USA	Vero E6	CPE	IFN-α, IFN-β	-	IFN-α = 1.35, IFN-β = 0.76 IU/mL	22
11	Caly L, 2020 ³⁰	Australia	Vero/hSLAM	12-well; TaqMan RT-PCR	Ivermectin	Viral DNA	2 µM	0, 72
12	Runfeng L, 2020 ²¹	China	Vero E6	MTT; CPE; Plaque	Lianhuaqingwen	RDV	411.2 µg/mL	72
13	Deng W, 2020 ²²	China	Vero E6	CPE	PDL	-	1.078 mg/mL	-
14	Wang M, 2020 ⁴	China	Vero E6	CCK8	RDV, CQ	NA	RDV - 0.77 µM, CQ - 1.13 µM	48
15	Choy KT, 2020 ²³	China	Vero E6	TCID50; qRT-PCR; CTG; LCVA	RDV, LPV, EH, HH	-	RDV = 23.15 µM, LPV = 26.63, EH = 0.46, HH = 2.55	48

Abbreviations: CCK8, Cell counting kit 8; Clrh, Cinnamifuga rhizome; Corh, Coptidis rhizome; CPE, Cytopathic effect inhibition assay; CQ, Chloroquine; CTG, CellTiter-Glo; CVA, Cell Viability Assay; DMSO, Dimethyl Sulfoxide; EH, Ementine Hydrochloride; HCQ, Hydroxychloroquine; HH, Homoharringtonine; IFN α/β, Interferon-α/β; Interferon-α/β, Interferon-α; L-CVA, Luminescent Cell Viability Assay; LPV, Lopinavir; Mcr, Mountain cortex radices; MEco, Meliae cortex; MTT, Methyl Thiazolyl Tetrazolium; NHC, Beta-d-N4-hydroxycytidine; NN-DNJ, N-Nonyldeoxyjirimycin; PDL, Pudilan Xiaoyan Oral Liquid; PHco, Phellodendron cortex; qRT-PCR, Qualitative Reverse Transcriptase Polymerase Chain Reaction; RDV, Remdesivir; Ssr, Sophora subprostrata radix; VNA, Virus Neutralization assay.

TABLE 2 Baseline characteristics of clinical studies included in the systematic review and meta-analysis

S. no	Author, year (country)	Study design (single/multicentre)	Total sample size	Overall age, mean (SD)	Total males, n (%)	Treatment	Comparator	Risk of bias
1	Tang W, 2020 ¹⁰ (China)	Phase-4, Open label RCT (Multicentre)	150	46.1 (14.7)	82	HCQ	Control	High
2	Chen J, 2020 ³¹ (China)	Phase-3, Open label RCT (Single)	30	48.6 (3.7)	21	HCQ	Control	High
3	Gautret P, 2020 ⁶ (France)	Open label non-RCT (Multicentre)	36	45.1 (22)	15	HCQ, HCQ + Azithromycin	Control	Some concerns
4	Geleris J, 2020 ⁴⁷ (USA)	Observational study (Single)	1376	.	781	HCQ	Control	Low
5	Yu B, 2020 ³² (China)	Retrospective cohort study (Single)	550	68 (13.38)	344	HCQ	Control	Some concerns
6	Magagnoli I, 2020 ⁴⁸ (USA)	Retrospective cohort study (Single)	807	68.53 (12.49)	772	HCQ, HCQ + Azithromycin	Control	Some concerns
7	Mahevas M, 2020 ⁵⁸ (France)	Retrospective observational study (Multicentre)	173	60 (11.96)	125	HCQ	Control	Some concerns
8	Rosenberg ES, 2020 ⁴⁹ (USA)	Retrospective cohort study (Multicentre)	1227	63	724	HCQ, HCQ + Azithromycin	Control	Low
9	Borba MGS, 2020 ⁵⁹ (Brazil)	Phase-2b, Parallel, double-blind RCT (Single)	81	51.1 (13.9)	61	Low dose CQ	High dose CQ	Low
10	Huang M, 2020 (a) ³⁴ (China)	Prospective Observational study (Multicentre)	373	44.65 (13.29)	175	CQ	Control	Some concerns
11	Huang M, 2020 (b) ³³ (China)	Open label RCT (Single)	22	46 (16.64)	13	CQ	Lopinavir-Ritonavir	High
12	Cao B, 2020 ³⁵ (China)	Open label RCT (Single)	199	58.33 (14.19)	120	Lopinavir-Ritonavir	Control	Some concerns
13	Ye XT, 2020 ³⁶ (China)	Retrospective observational study (Single)	47	.	22	Lopinavir-Ritonavir	Control	Some concerns
14	Jun C, 2020 ³⁷ (China)	Retrospective observational study (Single)	134	48.25 (5.19)	69	Lopinavir-Ritonavir + Arbidol	Control	Low
15	Li Y, 2020 ³⁸ (China)	Phase-4, Open label RCT (Single)	86	49.4 (14.7)	24	Lopinavir-Ritonavir + Arbidol	Control	Some concerns
16	Wang Y (a), 2020 ¹¹ (China)	Phase-3, Double-blind, Placebo-controlled RCT (Multicentre)	236	64 (11.19)	140	Remdesivir	Placebo	Low
17	Beigel JH, 2020 ⁵¹ (USA)	Phase-3, Double-blind, Placebo-controlled RCT (Multicentre)	1059	58.9 (15)	684	Remdesivir	Placebo	Low
18	Goldman JD, 2020 (USA) ⁵²	Open label RCT (Multicentre)	397	60.5 (14.93)	253	Remdesivir 5-day	Remdesivir 10-day	Some concerns
19	Cai Q, 2020 ³⁹ (China)	Open label non-RCT (Single)	80	47.92 (19.06)	35	Favipiravir	Lopinavir-Ritonavir	Some concerns
20	Cantini F, 2020 ⁵³ (Italy)	Open label non-RCT (Single)	24	63.57 (11.95)	20	Baricitinib	Control	Low

(Continues)

TABLE 2 (Continued)

S. no	Author, year (country)	Study design (single/multicentre)	Total sample size	Overall age, mean (SD)	Total males, n (%)	Treatment	Comparator	Risk of bias
21	Hung IFN, 2020 ⁶⁰ (Hong Kong)	Phase-2, Open label RCT (Multicentre)	127	48.67 (22.5)	68	Lopinavir/Ritonavir, Ribavirin, IFN-BI	Lopinavir-Ritonavir	High
22	Deng L, 2020 ⁴⁰ (China)	Retrospective cohort study (Single)	33	44.56 (15.73)	17	Lopinavir/ Ritonavir, Arbidol	Lopinavir-Ritonavir	Some concerns
23	Fadel R, 2020 ⁵⁰ (USA)	Quasi Experimental study (Multicentre)	213	61.96 (16.07)	109	Early-corticosteroid group	Late-corticosteroid group	Some concerns
24	Wang Y (b), 2020 ⁴¹ (China)	Retrospective cohort study (Single)	46	55.33 (12.24)	26	Corticosteroid	Control	Some concerns
25	Zha L, 2020 ⁴² (China)	Retrospective cohort study (Multicentre)	31	41.67 (17.1)	20	Corticosteroid	Control	Some concerns
26	Lu X, 2020 ⁴³ (China)	Case-Control study (Single)	62	58.66 (13.6)	32	Corticosteroid	Control	Low
27	Qin N, 2020 ⁴⁴ (China)	Retrospective observational study (Single)	72	49.33 (15.89)	41	Corticosteroid	Control	Some concerns
28	Cruz AF, 2020 (Spain) ⁶¹	Retrospective cohort study (Single)	463	65.79 (13.3)	73	Corticosteroid	Control	Some concerns
29	Liu X, 2020 ⁴⁵ (China)	Retrospective cohort study (Single)	22	55.27 (12.27)	15	Dipyridamole	Control	Some concerns
30	Li L, 2020 (China) ⁴⁶	Open label RCT (Multicentre)	103	70 (12.03)	60	Convalescent Plasma	Control	Some concerns
31	Guaraldi G, 2020 (Italy) ⁵⁴	Retrospective cohort study (Multicentre)	544	66.67 (15.61)	359	Tocilizumab	Control	Some concerns
32	Campochiaro C, 2020 (Italy) ⁵⁵	Retrospective cohort study (Single)	65	63.75 (16.47)	56	Tocilizumab	Control	Low
33	Colaneri M, 2020 (Italy) ⁵⁶	Retrospective cohort study (Single)	112	63.55 (16.95)	82	Tocilizumab	Control	Some concerns
34	Capra R, 2020 (Italy) ⁵⁷	Retrospective observational study (Single)	85	64.17 (13.95)	64	Tocilizumab	Control	Some concerns
35	Deftereos SG, 2020 ⁶² (Greece)	Open label RCT (Multicentre)	105	64.67 (16.54)	61	Colchicine	Control	Some concerns

Abbreviations: CQ, chloroquine; HCQ, hydroxychloroquine; IFN, interferon; USA, United States of America.




FIGURE 2 A-D, Meta-analysis of hydroxychloroquine vs control groups to assess (A) all-cause mortality, (B) total adverse events, (C) overall clinical recovery, (D) time to clinical recovery

clinical recovery in the lopinavir-ritonavir group compared to the control group (SMD -0.47 ; 95%CI -1.00 to 0.07) (Figure 3A-C). Due to less number of available studies, a meta-analysis could not be performed for assessing the all-cause mortality between the two groups.

3.3.3 | Lopinavir-ritonavir vs arbidol groups

The benefit/harm of lopinavir-ritonavir treatment over arbidol treatment was assessed in two studies^{37,38} consisting of 155 nCOV-2019 cases, 86 in the




FIGURE 3 A-C, Meta-analysis of lopinavir-ritonavir vs control groups to assess (A) total adverse events, (B) overall clinical recovery, (C) time to clinical recovery. D, E, Meta-analysis of lopinavir-ritonavir vs arbidol groups to assess (D) total adverse events, (E) overall clinical recovery

lopinavir-ritonavir treatment group and 69 in arbidol treatment group. Lopinavir-ritonavir treatment group was significantly associated with higher total adverse events as compared to the arbidol treatment group (RR 2.25; 95%CI 1.07 to 4.74). None of the two treatment groups were found to be associated with an increase in the overall

clinical recovery of nCOV-2019 patients (RR 0.95; 95%CI 0.78 to 1.15) (Figure 3D-E). The findings were concurrent when analysed using the Labbé plots (Appendix S2). A meta-analysis could not be performed for all-cause mortality and time to clinical recovery because of less number of studies.

3.3.4 | Arbidol vs control groups

Two studies^{37,38} consisting of 134 nCOV-2019 cases were included in the meta-analysis and were divided into two groups: 69 subjects to Arbidol group and 65 subjects to control group. When compared to the control group, treatment with Arbidol was not found to be associated with incidence of the total adverse events (RR 1.80; 95%CI 0.52 to 6.19) or overall clinical recovery (RR 1.08; 95%CI 0.85 to 1.38) (Figure 4A,B). The findings were concurrent when analysed using the Labbé plots (Appendix S2). A meta-analysis could not be performed for the remaining outcome measures of all-cause mortality and time to clinical recovery due to fewer number of studies.

3.3.5 | Remdesivir vs placebo group

The effect of remdesivir treatment over placebo was assessed in two RCTs^{11,51} consisting of 1295 nCOV-2019 patients and 696 in remdesivir group while 599 in placebo group. Compared to placebo group, remdesivir was not associated with either all-cause mortality (RR 0.74; 95%CI 0.40 to 1.37), total adverse events (RR 0.91; 95%CI 0.79 to 1.05) or time to clinical recovery (SMD -0.78 ; 95%CI -2.05 to 0.50). However, a significant association was observed with better overall clinical recovery (RR 1.17; 95%CI 1.07 to 1.29) in remdesivir group compared to placebo group (Figure 5A-D).

Similar findings were observed in Labbé plot analysis as well (Appendix S2).

3.3.6 | Corticosteroids vs control groups

Five studies^{41-44,61} consisting of 674 nCOV-2019 cases were included in the meta-analysis and were divided into two groups: 515 subjects to corticosteroid group and 159 subjects to control group. Administration of corticosteroid treatment was found to have no significant association with all-cause mortality (RR, 1.17; 95%CI 0.37 to 3.65) or the average time to clinical recovery (SMD 0.16; 95%CI -0.26 to 0.58) compared to the control group (Figure 6A,B). Since enough studies could not be pooled, no meta-analysis was performed to assess the effect of corticosteroid treatment on the total adverse events and overall clinical recovery.

3.3.7 | Tocilizumab vs control groups

Four studies⁵⁴⁻⁵⁷ consisting of 806 nCOV-2019 cases were included in the meta-analysis and were classified into two groups: 294 subjects to tocilizumab and 512 subjects in control groups. Tocilizumab was found to have significantly less all-cause mortality compared to the control group (RR 0.38; 95%CI 0.16 to 0.93). However, there was no significant difference between the two groups in terms of overall clinical recovery (RR 1.11; 95%CI 0.80 to 1.54). Due to less number




FIGURE 4 A, B, Meta-analysis of arbidol vs control groups to assess (A) total adverse events, (B) overall clinical recovery




FIGURE 5 A-D, Meta-analysis of remdesivir vs control groups to assess (A) all-cause mortality, (B) total adverse events, (C) overall clinical recovery, (D) time to clinical recovery

of studies, a meta-analysis was not possible for the other two outcomes of interest.

3.3.8 | Combination therapy

The combination of hydroxychloroquine and azithromycin was tested in three studies^{6,48,49} including 1591 nCOV-2019 cases wherein, 955 cases were allocated to the hydroxychloroquine + azithromycin treatment group and the rest 636 cases to the control group. The combination of hydroxychloroquine + azithromycin was significantly associated with a higher risk of all-cause mortality compared to the control group (RR 2.19; 95%CI 1.67 to 2.86), while no association was observed between the two in terms of overall clinical recovery (RR 1.05; 95%CI 0.77 to 1.42) (Figure 7A,B). However, we did observe a slight trend in a lesser overall clinical recovery towards the hydroxychloroquine + azithromycin treatment group using the Labbé plot (Appendix S2).

The total adverse events and time to clinical recovery outcomes could not be assessed due to limited number of studies.

3.4 | Publication bias

The publication bias was assessed using funnel plot analysis for all those treatment modalities wherein data from more than two studies could be pooled together. The shape of the funnel plots did not show any evidence of significant publication bias except for two instances wherein hydroxychloroquine was compared with control group to assess the overall clinical recovery outcome (P -value: .003) and lopinavir-ritonavir treatment was compared with control group to assess the total adverse event outcome (P -value: .02). This was confirmed by the significant p -values obtained from the Egger's regression test. The P -value of Egger's regression test was not significant for the presence of any publication bias for the rest of the funnel plots. Figure 8B represents the funnel plot analysis carried out for hydroxychloroquine vs control group for




FIGURE 6 A, B, Meta-analysis of corticosteroid vs control groups to assess (A) all-cause mortality, (B) time to clinical recovery. C, D, Meta-analysis of tocilizumab vs control groups to assess (C) all-cause mortality, (D) overall clinical recovery

assessing the overall clinical recovery outcome. The remaining funnel plots have been depicted in the Table S4 of Appendix S2.

3.5 | Meta-regression analysis

A meta-regression analysis was conducted to determine whether the risk of bias and ethnicity of each study were associated with the overall effect size difference. A meta-regression analysis was performed only for those treatments where data from more than two studies were pooled. The two predictor variables used in the meta-regression analysis were categorized as: risk of bias (low, some concerns, high) and ethnicity (Asian, Caucasian). The

'ethnicity' variable as a predictor was found to be significantly associated with the overall effect size difference while assessing the time to clinical recovery outcome between hydroxychloroquine and control group (P -value: .02) and assessing the all-cause mortality outcome between hydroxychloroquine and control group (P -value < .001) (Figure 8C) and similar outcome between corticosteroid and control group (P -value: .007). The 'risk of bias' variable as a predictor was also found to be significantly associated with the overall effect size difference while assessing the all-cause mortality outcome between corticosteroid and control group (P -value: .009) and while assessing the time to clinical recovery outcome between hydroxychloroquine and control group (P -value: .02). Risk of bias and ethnicity did




FIGURE 7 A, B, Meta-analysis of combination therapy. Meta-analysis of Hydroxychloroquine + Azithromycin vs Control groups to assess (A) all-cause mortality, (B) overall clinical recovery

not have any association with the overall effect size difference for assessing the remaining outcomes between other treatment groups.

3.6 | Quality (Risk of bias) assessment

The risk of bias was assessed using ROB-2 tool for RCTs and NOS for non-RCTs, cohort and case-control studies. For NOS, the total score was divided into three categories: (a) 1-3 (high risk of bias); (b) 4-6 (some concerns); (c) 7-9 (low risk of bias). Overall, 9 (25.71%) studies included in our review had an overall low risk of bias, 22 (62.86%) studies had some concerns related to the risk of bias, while four studies (11.43%) had high risk of bias. All the four studies^{10,31,33,60} with a high risk of bias belonged to the RCT subgroup (Figure 9A,B). The individual items for the quality scale are depicted in Appendix S1.

3.7 | Influence diagnostics and sensitivity analysis

Influence diagnostics tools and sensitivity analysis were used to further explain the heterogeneity observed in our results and to identify the outlier studies, which could be significantly affecting the overall pooled effect estimates. The influence diagnostics and sensitivity analysis were performed for treatments in which data from more than two studies were pooled. The influence diagnostic tools generated two plots including (a) Baujat plots; (b) influence analysis plots; and two plots for

sensitivity analysis including (c) leave-one-out analysis ordered by heterogeneity and (d) leave-one-out analysis ordered by effect size.

The Baujat and influence analysis plots identified one potential outlier namely, Yu B, 2020³² while assessing the all-cause mortality outcome in hydroxychloroquine vs. control group analysis. After conducting the sensitivity analysis by omitting a single study in each turn (ordered by both effect size and I^2), the overall effect size and amount of heterogeneity changed significantly by omitting the Yu B, 2020 study. Hydroxychloroquine was found to be significantly associated with the risk of having more all-cause mortality compared to control group (RR 1.57; 95%CI 1.30 to 1.90; $I^2 = 0\%$) (Figure 10). A borderline association was observed between hydroxychloroquine and less overall clinical recovery when Gautret P, 2020⁶ outlier study was omitted in the sensitivity analysis (RR 0.92; 95%CI 0.84 to 1.00; $I^2 = 67\%$).

The influence diagnostic tools identified Ye XT, 2020³⁶ study as a potential outlier while assessing the time to clinical recovery outcome between lopinavir-ritonavir and control groups; and after omitting this study in the sensitivity analysis, we observed that lopinavir-ritonavir was significantly associated with a shorter mean time to clinical recovery than the control group (SMD -0.32 ; 95%CI -0.57 to -0.06 , $I^2 = 0\%$).

While assessing the all-cause mortality outcome between corticosteroid and control groups, we observed Lu X, 2020⁴³ as a potential outlier study. After removing the outlier, a significant association was observed between




FIGURE 8 A, Labbé plot analysis for observing the trend and between-study heterogeneity in meta-analysis between hydroxychloroquine and control group for assessing the overall clinical recovery outcome. B, Funnel plot for publication bias analysis of hydroxychloroquine vs control group assessing the overall clinical recovery (Egger's P -value: .003). C, Meta-regression analysis for assessing the all-cause mortality outcome between hydroxychloroquine and control group using 'ethnicity' as predictor variable (P -value: <.001)

less all-cause mortality and corticosteroid treatment with reduced heterogeneity (RR 0.61; 95%CI 0.37 to 0.98, $I^2 = 0\%$).

The significant association between less all-cause mortality and tocilizumab treatment was lost when Capra R, 2020,⁵⁷ Guaraldi G, 2020⁵⁴ and Campochiaro C, 2020⁵⁵ were omitted sequentially in the sensitivity analysis.

4 | DISCUSSION

Our systematic review and meta-analysis summarized the in vitro and clinical studies so far regarding the effect of various treatment modalities administered to nCOV-2019 pneumonia patients. In vitro studies observed significant inhibitory effects of Remdesivir and Hydroxychloroquine on nCOV-2019.




FIGURE 9 A, B, Risk of bias assessment of the included studies in the systematic review using the (A) new Cochrane risk of bias tool for randomized controlled trials (ROB-2) and (B) Newcastle-Ottawa Scale for non-RCTs, cohort and case-control studies




FIGURE 10 Influence diagnostic tools and sensitivity analysis plots for identifying the potential outlier studies and assessing the heterogeneity in the pooled effect size for assessing the all-cause mortality outcome between hydroxychloroquine treatment and control group

Hydroxychloroquine was found to have a better efficacy and less cytotoxicity than Chloroquine in inhibiting nCOV-2019 while remdesivir had significant potency in blocking the viral infection. However, the clinical translation of promising in vitro results in some of these drugs has not been successful. In 35 clinical studies consisting of 9170 nCOV-2019 patients, we assessed the potential of several treatments against their comparators in terms of harm which included all-cause mortality and total adverse events and in terms of benefit which included overall clinical recovery and time to clinical recovery. While assessing the benefits of administered treatments, lopinavir-ritonavir treatment had a borderline association with shorter mean time to clinical recovery compared to the control group, remdesivir treatment had significant association with better overall clinical recovery compared to placebo group and tocilizumab was associated with less all-cause mortality compared to controls. However, the present evidence stems from only a few of trials/studies conducted on these drugs and the clinical usefulness of these results will only be determined once further large RCTs are published

on the same. In terms of harm, our meta-analysis suggests that hydroxychloroquine treatment compared to control group and lopinavir-ritonavir treatment compared to arbidol treatment were significantly associated with more total adverse events in nCOV-2019 patients. Hydroxychloroquine was also associated with a longer time to clinical recovery compared to control group. Hydroxychloroquine combined with azithromycin was associated with higher all-cause mortality compared to control group. We did not observe any significant association in terms of either benefit or harm for the remaining treatments administered to nCOV-2019 patients when analysed against their respective comparator groups. Although our systematic review of individual studies observed several treatments associated with benefit few including favipiravir, chloroquine, baricitinib, 5-day remdesivir treatment and certain treatments associated with harm including colchicine, corticosteroids and combination therapy of Hydroxychloroquine + Azithromycin in nCOV-2019 patients (Appendix S2); the results were reported only from single studies and thus lacked sufficient statistical power to

draw any profound conclusions. Around 62.86% of the studies included in our review had moderate/some concerns related to the risk of bias.

When we conducted the influence and sensitivity analysis, we observed that hydroxychloroquine was associated with a higher all-cause mortality and less overall clinical recovery (borderline association) in nCOV-2019 patients compared to the control group. The borderline association of Lopinavir-Ritonavir treatment having a shorter mean time to clinical recovery compared to control group was confirmed to be statistically significant after the sensitivity analysis. Further, tocilizumab was no longer associated with less all-cause mortality while corticosteroid treatment had a significant association with less all-cause mortality compared to control group. Our findings are in concordance with a review published in April 2020 by Sanders et al,⁶³ which reviewed the initial pharmacological treatments available for nCOV-2019 and concluded that no available therapy was found to be effective for treating this infection.

Initial evidence from *in vitro* and observational studies suggested that Hydroxychloroquine has comparatively faster viral clearance and results in better clinical improvement of nCOV-2019 patients in contrast to control groups.^{5,32} Further, the combination of hydroxychloroquine and azithromycin resulted in 100% clinical recovery in a small open label non-RCT published by Gautret et al.⁶ However, when early results from few RCTs were reported, hydroxychloroquine no longer had any benefit over standard care and instead was associated with more adverse events and higher mortality rate.^{10,31} We also conducted a subgroup analysis based on study design which further strengthened this notion. Hydroxychloroquine compared to control group was found to be associated with a longer time to clinical recovery in both non-RCTs/cohort study subgroup as well as in the RCT subgroup (Figure S2 in Appendix S2). Two recent meta-analyses conducted by Ren et al and Wang et al found that patients taking chloroquine or hydroxychloroquine had more adverse events compared to patients assigned to placebo group.^{64,65} Another meta-analysis published a couple of months ago by Sarma et al⁶⁶ found no association of hydroxychloroquine with virological cure, death or clinical worsening and safety in nCOV-2019 patients. Similar findings on hydroxychloroquine with or without azithromycin were observed from another meta-analysis of five trials which although did observe a trend but the results were not found to be statistically significant in terms of negative conversion of nCOV-2019 (odds ratio [OR] 1.95; 95%CI 0.19 to 19.73) and reduction in progression rate (OR 0.89 95%CI 0.58 to 1.37).⁶⁷ Our meta-analysis along with the subgroup and sensitivity analyses further corroborates these findings.

The effectiveness and safety of corticosteroid treatment in nCOV-2019, SARS and MERS have been investigated in several meta-analyses. Use of corticosteroid treatment was found to be associated with higher mortality (RR 2.11; 95%CI 1.13 to 3.94) in nCOV-2019 and SARS patients in a meta-analysis of

15 studies conducted by Yang et al,⁶⁸ while three meta-analyses found that corticosteroid use did not worsen/improve mortality in patients with nCOV-2019, SARS-Cov and MERS-Cov.⁶⁹⁻⁷¹ Further, the meta-analysis by Li et al⁷⁰ also observed a delayed time to virus clearance in the corticosteroid group compared to controls (MD 3.78; 95%CI 1.16 to 6.41). The findings of our meta-analysis are also in line with the previously published meta-analyses on corticosteroids. We did not observe any significant association between corticosteroid treatment and all-cause mortality and time to clinical recovery, but after conducting the sensitivity analysis, we observed a significant association between less all-cause mortality and corticosteroid treatment after removing the outlier study. However, the result stems from a pooled synthesis of only a couple of trials and further large RCTs are required to confirm/refute our findings.

Use of convalescent plasma has been shown to be extremely promising in some recently published case series.^{72,73} Only one RCT was available on determining the effectiveness of convalescent plasma compared to controls,⁴⁶ thus we could not conduct a meta-analysis. However, we systematically reviewed the trial and observed that convalescent plasma was neither associated with more/less adverse events nor with more/less overall clinical recovery compared to control group (Appendix S2). However, we observed a trend of more overall clinical recovery towards the convalescent plasma arm (RR 1.20; 95% CI 0.80 to 1.81). A recently published systematic review of five studies by Rajendran et al⁷⁴ concluded that plasma therapy in nCOV-2019 patients was safe, clinically effective and was associated with a reduced mortality. Results from ongoing clinical trials on plasma therapy are awaited and will give us a better insight into the effectiveness of convalescent plasma in treating nCOV-2019 patients.

4.1 | Limitations

Although we made sure that our systematic review and meta-analysis was conducted very comprehensively, certain inherent and obvious limitations cannot be ignored. Firstly, due to the limited number of studies, our meta-analysis pooled the data from RCTs and non-RCTs/cohort/case-control studies together which is generally not advisable. However, we did conduct a subgroup analysis based on study design wherever possible to separate the RCTs from non-RCTs/cohort/case-control studies. Secondly, all outcome measures could not be assessed for all the potential treatments due to scarcity of literature. Lastly, since several clinical trials on nCOV-2019 treatments are currently ongoing, the results of our meta-analysis might change significantly owing to the findings published in near future.

Nonetheless, our meta-analysis presents preliminary evidence of benefit/harm of the possible treatments being administered to nCOV-2019 patients and these preliminary

results could be used for conducting and planning large clinical trials and prospective multicentric cohort studies.

5 | CONCLUSION

The result of this systematic review and meta-analysis suggests that hydroxychloroquine and remdesivir have shown promising results in the in vitro studies. However, based on the current clinical evidence, our meta-analysis did not observe significant beneficial effect of any treatment on nCoV-2019 patients apart from a significant association in better overall clinical recovery of remdesivir compared to placebo, less all-cause mortality in tocilizumab arm compared to controls and a borderline association in time to clinical recovery of lopinavir-ritonavir treatment compared to control group. Hydroxychloroquine with or without azithromycin might be associated with higher all-cause mortality, more total adverse events, less overall clinical recovery and a longer mean time to clinical recovery. Results from further large clinical trials are warranted.

CONFLICT OF INTEREST

There is no potential conflict of interest among the authors.

AUTHOR CONTRIBUTIONS

DV was the guarantor of the entire manuscript for designing, supervising and conceptualizing the entire study. SM was responsible for writing the first manuscript draft, literature search, data collection and statistical analysis. MN was responsible for literature search, data collection, quality assessment and results interpretation. VH provided guidance for writing results and discussion sections, was in-charge of correction of final manuscript draft and results interpretation.

ORCID

Shubham Misra  <https://orcid.org/0000-0002-4920-2573>

Manabesh Nath  <https://orcid.org/0000-0001-5979-8377>

Deepti Vibha  <https://orcid.org/0000-0003-3659-7526>

REFERENCES

- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733.
- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*. 2020;20(5):533-534.
- de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. *Nat Rev Microbiol*. 2016;14(8):523-534.
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 2020;30(3):269-271.
- Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020;71(15):732-739.
- Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020;56(1):105949.
- NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19 | NIH: National Institute of Allergy and Infectious Diseases. <http://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19>. Accessed May 21, 2020
- Vincent AL. EUA hydroxychloroquine sulfate health care provider fact sheet 04272020. 7.
- Commissioner O of the. Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment. FDA. 2020. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment>. Accessed May 21, 2020
- Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ*. 2020;369:m1849.
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet Lond Engl*. 2020;395(10236):1569-1578.
- Research C for DE and. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. FDA; 2020. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or>. Accessed May 21, 2020
- Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4:1.
- Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed May 21, 2020
- Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:14898.
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-634.
- Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol*. 2014;14:135.
- Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. *Cell Discov*. 2020;6(1):1-5.
- Kim H-Y, Shin H-S, Park H, et al. In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma, Meliae cortex, Coptidis rhizoma, and Phellodendron cortex. *J Clin Virol*. 2008;41(2):122-128.
- Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov*. 2020;6(1):1-4.
- Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). *Pharmacol Res*. 2020;156:104761.

22. Deng W, Xu Y, Kong Q, et al. Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo. *Signal Transduct Target Ther.* 2020;5(1):1-3.
23. Choy K-T, Wong AY-L, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. *Antiviral Res.* 2020;178:104786.
24. Wu Y, Li C, Xia S, et al. Identification of human single-domain antibodies against SARS-CoV-2. *Cell Host Microbe.* 2020;27(6):891-898.e5.
25. Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Sci Transl Med.* 2020;12(541):eabb5883.
26. Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. *Antiviral Res.* 2020;179:104811.
27. Rothan HA, Stone S, Natekar J, Kumari P, Arora K, Kumar M. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells. *Virology.* 2020;547:7-11.
28. De Meyer S, Bojkova D, Cinatl J, et al. Lack of antiviral activity of darunavir against SARS-CoV-2. *Int J Infect Dis.* 2020;97:7-10.
29. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat Commun.* 2020;11(1):1-6.
30. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.* 2020;178:104787.
31. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. *Zhejiang Xue Xue Bao Yi Xue Ban J Zhejiang Univ Med Sci.* 2020;49(2):215-219.
32. Yu B, Li C, Chen P, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. *Sci China Life Sci.* 2020;63:1-7.
33. Huang M, Tang T, Pang P, et al. Treating COVID-19 with Chloroquine. *J Mol Cell Biol.* 2020;12(4):322-325.
34. Huang M, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. *Natl Sci Rev.* 2020. <https://doi.org/10.1093/nsr/nwaa113>. [Epub ahead of print].
35. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. *N Engl J Med.* 2020;382(19):1787-1799.
36. Ye X-T, Luo Y-L, Xia S-C, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. *Eur Rev Med Pharmacol Sci.* 2020;24(6):3390-3396.
37. Jun C, Yun L, Xiuhong X, et al. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. *Chin J Infect Dis.* 2020;38:E008.
38. Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. *Med.* 2020. <https://doi.org/10.1016/j.medj.2020.04.001>. [Epub ahead of print].
39. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. *Eng Beijing China.* 2020. <https://doi.org/10.1016/j.eng.2020.03.007>. [Epub ahead of print].
40. Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. *J Infect.* 2020;81(1):e1-e5.
41. Wang Y, Jiang W, He Q, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. *Signal Transduct Target Ther.* 2020;5(1):57.
42. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). *Med J Aust.* 2020;212(9):416-420.
43. Lu X, Chen T, Wang Y, Wang J, Yan F. Adjuvant corticosteroid therapy for critically ill patients with COVID-19. *Crit Care Lond Engl.* 2020;24(1):241.
44. Qin N, Cheng D, Yongtao L, et al. Retrospective study of low-to-moderate dose glucocorticoids on viral clearance in patients with novel coronavirus pneumonia. *Chin J Clin Infect Dis.* 2020;13:E009.
45. Liu X, Li Z, Liu S, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. *Acta Pharm Sin B.* 2020;10:1205-1215.
46. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. *JAMA.* 2020;324:460.
47. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. *N Engl J Med.* 2020;382(25):2411-2418.
48. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. *Med.* 2020. <https://doi.org/10.1016/j.medj.2020.06.001>. [Epub ahead of print].
49. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. *JAMA.* 2020;323(24):2493-2502.
50. Fadel R, Morrison AR, Vahia A, et al. Early short course corticosteroids in hospitalized patients with COVID-19. *Clin Infect Dis.* 2020;ciaa601. <https://doi.org/10.1093/cid/ciaa601>. [Epub ahead of print].
51. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the TREATMENT of Covid-19 — preliminary report. *N Engl J Med.* 2020. <https://doi.org/10.1056/NEJMoa2007764>. [Epub ahead of print].
52. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *N Engl J Med.* 2020;NEJMoa2015301. <https://doi.org/10.1056/NEJMoa2015301>. [Epub ahead of print].
53. Cantini F, Niccoli L, Matarrese D, Nicastrì E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. *J Infect.* 2020;81(2):318-356.
54. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. *Lancet Rheumatol.* 2020;2(8):E474-E484.
55. Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. *Eur J Intern Med.* 2020;76:43-49.
56. Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for Treatment of severe COVID-19 patients: preliminary results from SMAteo COVID19 REgistry (SMACORE). *Microorganisms.* 2020;8(5):695.
57. Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. *Eur J Intern Med.* 2020;76:31-35.
58. Mahévas M, Tran V-T, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who

- require oxygen: observational comparative study using routine care data. *BMJ*. 2020;369:m1844.
59. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. *JAMA Netw Open*. 2020;3(4):e208857.
 60. Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet Lond Engl*. 2020;395(10238):1695-1704.
 61. Fernández Cruz A, Ruiz-Antorán B, Muñoz Gómez A, et al. Impact of glucocorticoid treatment in SARS-CoV-2 infection mortality: a retrospective controlled cohort study. *Antimicrob Agents Chemother*. 2020;64(9):e01168-20. <https://doi.org/10.1128/AAC.01168-20>
 62. Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with Coronavirus Disease 2019: the GRECCO-19 randomized clinical trial. *JAMA Netw Open*. 2020;3(6):e2013136.
 63. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): a review. *JAMA*. 2020;323(18):1824-1836.
 64. Ren L, Xu W, Overton JL, Yu S, Chiamvimonvat N, Thai PN. Assessment of hydroxychloroquine and chloroquine safety profiles: a systematic review and meta-analysis. *medRxiv*. 2020. 2020.05.02.20088872. <https://www.medrxiv.org/content/10.1101/2020.05.02.20088872v1>. Accessed May 20, 2020.
 65. Wang J, Yu L, Li K. Benefits and risks of chloroquine and hydroxychloroquine in the treatment of viral diseases: a meta-analysis of placebo randomized controlled trials. *medRxiv*. 2020. 2020.04.13.20064295. <https://www.medrxiv.org/content/10.1101/2020.04.13.20064295v1>. Accessed May 20, 2020.
 66. Sarma P, Kaur H, Kumar H, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis. *J Med Virol*. 2020;92(7):776-785.
 67. Yang T-H, Chou C-Y, Yang Y-F, et al. Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in COVID-19. *medRxiv*. 2020. 2020.05.07.20093831. <https://www.medrxiv.org/content/10.1101/2020.05.07.20093831v2>. Accessed May 20, 2020.
 68. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. *J Infect*. 2020;81(1):e13-e20.
 69. Gangopadhyay KK, Mukherjee JJ, Sinha B, Ghosal S. The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): a meta-analysis. *medRxiv*. 2020. 2020.04.17.20069773. <https://www.medrxiv.org/content/10.1101/2020.04.17.20069773v1>. Accessed May 20, 2020
 70. Li H, Chen C, Hu F, et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. *Leukemia*. 2020;34(6):1503-1511.
 71. Lu S, Zhou Q, Huang L, et al. Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis. *medRxiv*. 2020. 2020.04.17.20064469. <https://www.medrxiv.org/content/10.1101/2020.04.17.20064469v1>. Accessed May 20, 2020.
 72. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients With COVID-19 with convalescent plasma. *JAMA*. 2020;323(16):1582-1589.
 73. Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. *J Korean Med Sci*. 2020;35(14):e149.
 74. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. *J Med Virol*. 2020;92:1475-1483.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Misra S, Nath M, Hadda V, Vibha D. Efficacy of various treatment modalities for nCoV-2019: A systematic review and meta-analysis. *Eur J Clin Invest*. 2020;50:e13383. <https://doi.org/10.1111/eci.13383>